Martin Hirst
Papers
1
Total Citations
42
H-Index
1
About
Martin Hirst is a leading figure in cancer genomics, whose work has fundamentally advanced the clinical application of next-generation sequencing. His primary research focuses on the development and validation of high-throughput diagnostic assays for hereditary cancer syndromes, with a particular emphasis on the BRCA1 and BRCA2 genes. Hirst’s most cited work, a 2013 study on a clinically validated second-generation sequencing assay for detecting hereditary BRCA mutations, has been cited over 40 times and stands as a landmark in the field. This contribution demonstrated the feasibility of moving complex genomic technologies from the research bench into routine clinical diagnostics, directly impacting patient care by enabling more accurate and comprehensive risk assessment for breast and ovarian cancers. Beyond this flagship paper, Hirst’s broader portfolio includes pioneering efforts in epigenomics and the functional characterization of the cancer genome. His achievements have been recognized through numerous collaborative grants and leadership roles in large-scale genomic projects, cementing his reputation as a translational scientist who bridges the gap between genomic discovery and tangible clinical utility.
Research Focus
Key Achievements
Top Papers
- 1